Study of Lanreotide to Treat Polycystic Kidney Disease

PHASE3UnknownINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

August 31, 2017

Study Completion Date

December 31, 2017

Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
DRUG

Lanreotide

Lanreotide will be administered once every 4 weeks as a subcutaneous injection

Trial Locations (4)

Unknown

University Medical Center Groningen, Groningen

Leiden University Medical Center, Leiden

Radboud University Medical Center, Nijmegen

Erasmus Medisch Centrum, Rotterdam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Leiden University Medical Center

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

Radboud University Medical Center

OTHER

lead

University Medical Center Groningen

OTHER